Overview
- The 10,000‑square‑foot Carlsbad facility is Novartis’ third U.S. site for radioligand therapy manufacturing.
- Novartis has filed the site with the FDA as an additional U.S. supply point, with manufacturing to begin after approval.
- The plant is designed to support time‑sensitive, custom RLT doses and bolster on‑time delivery for patients in the western U.S., Alaska and Hawaii.
- The opening marks a milestone in Novartis’ $23 billion U.S. infrastructure plan, part of a broader investment approaching $50 billion over five years.
- The company reiterated plans for new RLT facilities in Florida and Texas, expansions in Millburn, Durham and Indianapolis, and a new biomedical research hub in San Diego.